Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data - Heribert Knechten, MD PZB Aachen, Germany T = 5

Monitoring HIV tropism and Maraviroc regimens in clinical routine - 24 weeks of follow-up data - N = 51 HIV-1 subtype B 86% Phenotype + Genotype N = 32 Phenotype only N = 6 Genotype onlyN = 13 Median Active Drug Score (ADS*) 3 Abstract No.: TUPDB202 Results Week 24N = 42 Median Viral load < 40 copies/mL MedianCD4 count 565 cells/µl (BL 415 cells/µl) Therapy successN = 32 (76.2%) * including MVC

Discordant Tropism results Patient ID Geno2pheno [FPR=10%] Geno2pheno [FPR=20%] standard TROFILE Viral load / 24 weeks ADS #1CXCR4 CCR5<403 #2CCR5CXCR4CCR5<404 #3CCR5CXCR4CCR5<404 #4CXCR4 CCR537,922 (W12) 2 #5CXCR4 CCR5<403 Positive Predictive Value:g2p (FPR 10%)77.2% g2p (FPR 20%) 73.7% TROFILE™ 78.2% Positive predictive values for geno2pheno and TROFILE in predicting R5-tropic viruses FPR: false positive rate is the probability of classifying an R5-viruses falsely as X4

Virological response in groups with different active drug scores (ADS incl. Maraviroc) ADS ≥4 week ADS 3 - 4ADS < 3 ADS according to resistant = 0; intermediate = 0.33; Limited susceptibility = 0.66; susceptible = 1; hypersusceptibility = 1.33 susceptible = 1; hypersusceptibility = 1.33 median

Thanks to: Stefan Christensen, Medical Practice, Münster, Germany; Martin Hower, Städt. Klinik Dortmund, Germany; Hans Jäger, MUC Research, Munich, Germany; Wolfgang Köthemann, Medical Practice, Cologne, Germany; Anton Neuwirth, Medical Practice, Cologne, Germany; Eiko Schnaitmann, Medical Practice, Stuttgart, Germany; Stefan Scholten, Medical Practice, Cologne, Germany; Andreas Trein, Medical Practice, Stuttgart, Germany; Eva Wolf, MUC Research, Munich, Germany;